{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:26:39Z","timestamp":1790403999776,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"17","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s40265-019-01215-9","type":"journal-article","created":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T14:03:41Z","timestamp":1572617021000},"page":"1897-1903","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Tenapanor: First Approval"],"prefix":"10.1007","volume":"79","author":[{"given":"Anthony","family":"Markham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,1]]},"reference":[{"key":"1215_CR1","unstructured":"US Food and Drug Administration. Ibsrela (tenapanor) tablets, for oral use: NDA approval letter. 2019. \nhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2019\/211801Orig1s000ltr.pdf\n\n. Accessed 22 Oct 2019."},{"key":"1215_CR2","unstructured":"AstraZenaca, Ardelyx. AstraZeneca and Ardelyx announce worldwide licensing deal for NHE3 Inhibitor Programme for complications of renal disease, including diabetes-induced renal disease [media release]. 8 Oct 2012. \nhttp:\/\/www.astrazeneca.com\n\n."},{"key":"1215_CR3","unstructured":"Ardelyx. IBSRELA (tenapanor) tablets, for oral use: US prescribing information. 2019. \nhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211801s000lbl.pdf\n\n. Accessed 22 Oct 2019."},{"issue":"4","key":"1215_CR4","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40261-017-0614-0","volume":"38","author":"DP Rosenbaum","year":"2018","unstructured":"Rosenbaum DP, Yan A, Jacobs JW. Pharmacodynamics, safety, and tolerability of the NHE3 inhibitor tenapanor: two trials in healthy volunteers. Clin Drug Investig. 2018;38(4):341\u201351.","journal-title":"Clin Drug Investig."},{"issue":"12","key":"1215_CR5","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s40265-018-0950-2","volume":"78","author":"D Fouque","year":"2018","unstructured":"Fouque D, Vervloet M, Ketteler M. Targeting gastrointestinal transport proteins to control hyperphosphatemia in chronic kidney disease. Drugs. 2018;78(12):1171\u201386.","journal-title":"Drugs."},{"key":"1215_CR6","unstructured":"Ardelyx. Ardelyx regains worldwide development and commercialization rights for its late-stage development candidate, tenapanor, and related portfolio of NHE3 compounds [media release]. 3 Jun 2015. \nhttp:\/\/www.ardelyx.com\n\n."},{"key":"1215_CR7","unstructured":"Ardelyx, Kyowa Hakko Kirin. Ardelyx and Kyowa Hakko Kirin announce license agreement for tenapanor for cardiorenal diseases in Japan [media release]. 28 Nov 2017. \nhttp:\/\/www.ardelyx.com\n\n."},{"key":"1215_CR8","unstructured":"Ardelyx. Ardelyx announces license agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for tenapanor in China [media release]. 11 Dec 2017. \nhttp:\/\/www.ardelyx.com\n\n."},{"key":"1215_CR9","unstructured":"Knight Therapeutics. Knight announces exclusive license agreement with Ardelyx for tenapanor [media release]. 19 Mar 2018. \nhttp:\/\/www.gudknight.com\n\n."},{"key":"1215_CR10","unstructured":"Ardelyx. Ardelyx and Knight collaborate to bring tenapanor to patients in Canada [media release]. 19 Mar 2018. \nhttp:\/\/www.ardelyx.com\n\n."},{"issue":"456","key":"1215_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aam6474","volume":"10","author":"AJ King","year":"2018","unstructured":"King AJ, Siegel M, He Y, et al. Inhibition of sodium\/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. Sci Transl Med. 2018;10(456):1\u201317.","journal-title":"Sci Transl Med."},{"key":"1215_CR12","doi-asserted-by":"publisher","first-page":"S255","DOI":"10.14309\/00000434-201710001-00484","volume":"112","author":"Qian Li","year":"2017","unstructured":"Li Q, King AJ, Liu L, et al. Tenapanor reduces IBS pain through inhibition of TRPV1-dependent neuronal hyperexcitability in vivo [abstract no. 484 and poster P2027]. Am J Gastroenterol. 2017;112(Suppl. 1):S255.","journal-title":"American Journal of Gastroenterology"},{"issue":"5","key":"1215_CR13","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1002\/cpdd.346","volume":"6","author":"S Johansson","year":"2017","unstructured":"Johansson S, Rosenbaum DP, Ahlqvist M, et al. Effects of tenapanor on cytochrome P450-mediated drug-drug interactions. Clin Pharmacol Drug Dev. 2017;6(5):466\u201375.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"1215_CR14","doi-asserted-by":"publisher","first-page":"S226","DOI":"10.14309\/00000434-201710001-00421","volume":"112","author":"William D. Chey","year":"2017","unstructured":"Chey WD, Lembo AJ, Korner P, et al. Efficacy and safety of tenapanor in patients with constipation predominant irritable bowel syndrome: a 12-week, double-blind, placebo-controlled, randomized phase 3 trial [abstract no. 421]. Am J Gastroenterol. 2017;112(Suppl. 1):S226\u2013S7.","journal-title":"American Journal of Gastroenterology"},{"issue":"6","key":"1215_CR15","doi-asserted-by":"publisher","first-page":"S","DOI":"10.1016\/S0016-5085(18)34452-4","volume":"154","author":"William D. Chey","year":"2018","unstructured":"Chey WD, Lembo AJ, Yan A, et al. Efficacy and safety of tenapanor in patients with constipation predominant irritable bowel syndrome: a 6-month, double-blind, placebo-controlled phase 3 trial (T3mpo-2) [abstract no. 885]. Gastroenterology. 2018;154(6 Suppl. 1):S-1362.","journal-title":"Gastroenterology"},{"issue":"5","key":"1215_CR16","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/ajg.2017.41","volume":"112","author":"WD Chey","year":"2017","unstructured":"Chey WD, Lembo AJ, Rosenbaum DP. Tenapanor treatment of patients with constipation-predominant irritable bowel syndrome: a phase 2, randomized, placebo-controlled efficacy and safety trial. Am J Gastroenterol. 2017;112(5):763\u201374.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"1215_CR17","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1681\/ASN.2018080832","volume":"30","author":"GA Block","year":"2019","unstructured":"Block GA, Rosenbaum DP, Yan A, et al. Efficacy and safety of tenapanor in patients with hyperphosphatemia receiving maintenance hemodialysis: a randomized phase 3 trial. J Am Soc Nephrol. 2019;30(4):641\u201352.","journal-title":"J Am Soc Nephrol"},{"key":"1215_CR18","unstructured":"Ardelyx. Ardelyx announces positive results from the pivotal phase 3 AMPLIFY study evaluating tenapanor in dialysis patients who have uncontrolled hyperphosphatemia despite phosphate binder treatment [media release]. 3 Sep 2019. \nhttp:\/\/www.ardelyx.com\n\n."},{"issue":"6","key":"1215_CR19","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1681\/ASN.2016080855","volume":"28","author":"GA Block","year":"2017","unstructured":"Block GA, Rosenbaum DP, Leonsson-Zachrisson M, et al. Effect of tenapanor on serum phosphate in patients receiving hemodialysis. J Am Soc Nephrol. 2017;28(6):1933\u201342.","journal-title":"J Am Soc Nephrol"},{"key":"1215_CR20","doi-asserted-by":"crossref","unstructured":"Lembo A, Chey WD, Rosenbaum DP. An open label long-term safety trial (T3MPO-3) of tenapanor in patients With irritable bowel syndrome with constipation (IBS-C) [abstract no. 430 and poster P0338]. Am J Gastroenterol. 2018;113(Suppl.):S252.","DOI":"10.14309\/00000434-201810001-00430"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01215-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-019-01215-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01215-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T00:43:04Z","timestamp":1604104984000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-019-01215-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":20,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["1215"],"URL":"https:\/\/doi.org\/10.1007\/s40265-019-01215-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"1 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. A. Markham, a contracted employee of Adis International Ltd\/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}